Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.62 |
| ▸ | BACE1 | P56817 | 8/20 | 0.62 |
| ▸ | BCHE | P06276 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259147 | 0.91 | BACE1 (0.64) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL2885290 | 0.91 | BACE1 (0.64) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL13761943 | 0.91 | BACE1 (0.64) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL13548837 | 0.86 | ACHE (0.57) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL1448701 | 0.85 | ACHE (0.56) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL21569736 | 0.83 | ACHE (0.50) | ACHEBACE1BCHESIGMAR1ALDH1A1 | |
| SCHEMBL12617587 | 0.82 | ALDH1A1 (0.56) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL13761638 | 0.82 | ALDH1A1 (0.60) | ACHEBACE1BCHEALDH1A1KDM4E | |
| SCHEMBL12617233 | 0.82 | MEN1 (0.62) | ACHEBACE1MEN1KMT2ASIGMAR1 | |
| SCHEMBL4848458 | 0.82 | MEN1 (0.55) | ACHEBACE1BCHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025036241-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING | RIBOPEUTIC INC. (CN) | 2025-02-20 | — | — | WO | disclosed |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | disclosed |
| EP-3846814-A1 | SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES | Genoscience Pharma (FR) | 2021-07-14 | — | — | EP | disclosed |
| CN-112912081-A | Substituted 2, 4-diamino-quinolines as novel agents for fibrosis, autophagy and cathepsin B (CTSB), L (CTSL) and D (CTSD) related diseases | 基因科学医药公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | EMORY UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-10722505-B2 | Substituted 2,4 diamino-quinoline as new anticancer agents | GENOSCIENCE PHARMA (FR) | 2020-07-28 | — | — | US | disclosed |
| US-10722505-B2 | Substituted 2,4 diamino-quinoline as new anticancer agents | GENOSCIENCE PHARMA (FR) | 2020-07-28 | — | — | US | disclosed |
| CN-107148416-B | Substituted 2,4 diamino-quinolines as novel anticancer agents | 基因科学医药公司 | 2020-05-05 | — | — | CN | disclosed |
| US-20200079781-A1 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2020-03-12 | — | — | US | disclosed |
| EP-3620164-A1 | SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES | Genoscience Pharma SAS (FR) | 2020-03-11 | — | — | EP | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
| CN-1708493-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558600-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004037810-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | RORA, RORB, RORC | ACHE 3809/4885BACE1 3787/4885BCHE 1519/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ACHE 1631/4885BACE1 1133/4885BCHE 1548/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACHE 1031/4885BACE1 319/4885BCHE 2131/4885 |
| US-10722505-B2 | Substituted 2,4 diamino-quinoline as new anticancer agents | NQO2, TP53, CDK4 | ACHE 2711/4885BACE1 4303/4885BCHE 3687/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | ACHE 1667/4885BACE1 1289/4885BCHE 1446/4885 |
| US-20200079781-A1 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | ACHE 2467/4885BACE1 677/4885BCHE 2626/4885 |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | ACHE 2467/4885BACE1 677/4885BCHE 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.